Medicaid managed care: Disparities in the use of thiazolidinediones compared with metformin

Journal of the National Medical Association

Volumn 97, Issue 4, 2005, Pages 493-497

  Shaya, Fadia T ^a,b,c,e   Shin, James Y ^a,b   Mullins, C Daniel ^a,c   Fatodu, Hugh O ^a,e   Gu, Anna ^a   Saunders, Elijah ^a,d  

^a Sch of Epidemiol/Prev Medicine ^*

^b Sch of Epidemiol/Prev Medicine   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Diabetes; Managed care; Medicaid; Race; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; TROGLITAZONE;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEALTH CARE PLANNING; HEART FAILURE; HUMAN; INCIDENCE; INSULIN TREATMENT; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAID; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URBAN POPULATION;

COHORT STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; MEDICAID; METFORMIN; MULTIVARIATE ANALYSIS; ODDS RATIO; PROBABILITY; RETROSPECTIVE STUDIES; RISK FACTORS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 16244393684     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Centers for Disease Contral and Prevention-National Center for Injury Prevention and Control, http://webapp.cdc.gov/sasweb/ncipc/lead-caus10.html. Accessed 09/12/03.
2. Centers for Disease Control and Prevention, National Institutes of Health: Healthy People 2010: Objectives for Improving. P. 5.3-5.39
3. Harris MI, Eastman RC: Early detection of undiagnosed diabetes mellitus: A U.S. perspective. Diabetes/Metabolism Research Reviews. 2000;16:230-236.
4. CBSNews story "Diabetes, could you have it?" 11/04/03. Available from www.cbsnews.com/stories/2003/11/03/earlyshow/health/ main581430.shtml. Accessed 11/06/03.
5. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
6. Sherwin RS, Anderson RM, Buse JB, et al. The prevention or delay of type-2 diabetes. Diabetes Care. 2003;26:S62-S69.
7. Wong MD, Shapiro MF, Boscardin WJ, et al. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347:1585-1592.
8. CDC Diabetes Program-National Diabetes Fact Sheet, 2003. www.cdc.gov/ diabetes/pubs/estimates.htm#prev4. Accessed 09/29/03.
9. Smedley BD, Stith AY, Nelson AR, ed. Unequal treatment: confronting racial and ethnic disparities in health care. The National Academies Press. Washington DC, 2003.
10. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type-2 diabetes. J Clin Endocrinol Metab. 2003;88:1637-1645.
11. Yu J, Kruszynska YT, Mulford MI, et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type-2 diabetic patients. Diabetes. 1999;48:2414-2421.
12. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type-2 diabetes. Diabetes Care. 2002;25:2244-2248.
13. Ahmann AJ, Riddle MC. Current oral agents for type-2 diabetes: many options, but which to choose when? Postgrad Med. 2002;111:32-46.
14. National Institute for Clinical Excellence: Guidance on the use of glitazones for the treatment of type-2 diabetes. Technology appraisal 63, August 2003.
15. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type-2 diabetes. J Clin Endocrinol Metab. 2001;86: 280-288.
16. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type-2 diabetes. Diabetes Care. 2002;25:1691-1698.
17. Yu J, Kruszynska YT, Mulford MI, et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type-2 diabetic patients. Diabetes. 1999;48:2414-2421.
18. Reikes ST. Trends in end-stage renal disease: epidemiology, morbidity and mortality. Postgrad Med. 2000;108:124-142.
19. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type-II diabetes. J Hum Hypertens. 2003;17:7-12.
20. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type-2 diabetes (UKPDS 34) Lancet. 1998;352:854-865.
21. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clinic Proceedings. 2003;78:1088-1091.
22. Actos prescribing information. 2003. www.actos.com. Accessed 11/18/03.
23. Avandia prescribing information, 2003. http://us.gsk.com/products/ assets/us_avandia.pdf. Accessed 11/18/03.
24. Davis SK, Liu Y, Gibbons GH. Disparities in trends of hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: implications and benchmarks. Am J Public Health. 2003;93: 447-455.
25. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care and outcomes of elderly patients hospitalized with heart failure. JAMA. 2003;289:2517-2524.
26. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, TX: American Heart Association; 2003.
27. Kalon KHL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(SupplA)6A-13A.
28. Kaiser Family Foundation Employer Health Benefits Survey, 2003. www.kff.org/content/2003/20030909a/SOFv2.pdf. Accessed 09/29/03.
29. Actos/Avandia-one year on. www.ims-global.cam/insight/news_ story/0006/news_story_000629a.htm. Accessed 09/30/03.
30. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type-2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.